Theriva Biologics, Inc.: Theriva Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer

ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in

Related Keywords

United States ,American ,Stevena Shallcross ,Chris Calabrese ,Theriva Biologics ,Theriva Biologics Inc ,Drug Administration ,Company Annual Report On Form ,Lifesci Advisors ,Fast Track Designation ,Chief Executive Officer ,Theriva Biologic ,Private Securities Litigation Reform Act ,Annual Report ,Sci Advisors ,Ihr Portfolio ,